Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20199755 | 0.96 | MAPT (0.36) | MAPTMAPK1TSHRNPSR1HSD17B10 | |
| SCHEMBL20199596 | 0.95 | MAPT (0.37) | MAPTMAPK1TSHRNPSR1HSD17B10 | |
| SCHEMBL20199636 | 0.90 | KDM4E (0.36) | MAPTMAPK1HPGDALDH1A1KDM4E | |
| SCHEMBL23184510 | 0.88 | MAPT (0.35) | MAPTMAPK1TSHRNPSR1HSD17B10 | |
| SCHEMBL20199633 | 0.88 | KDM4E (0.31) | MAPTMAPK1TSHRHSD17B10HPGD | |
| SCHEMBL23184237 | 0.87 | MAPT (0.33) | MAPTMAPK1TSHRNPSR1HSD17B10 | |
| SCHEMBL20199634 | 0.87 | MAPT (0.36) | MAPTMAPK1NPSR1HPGDALDH1A1 | |
| SCHEMBL20199499 | 0.87 | MAPT (0.39) | MAPTMAPK1TSHRNPSR1HSD17B10 | |
| SCHEMBL20199756 | 0.86 | KDM4E (0.36) | MAPTHPGDALDH1A1KDM4E | |
| SCHEMBL20199655 | 0.86 | MAPT (0.36) | MAPTMAPK1TSHRNPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001752-B2 | Double spiro organic compound and organic electronic element comprising same | LG CHEM, LTD. (KR) | 2021-05-11 | — | — | US | disclosed |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001752-B2 | Double spiro organic compound and organic electronic element comprising same | DCX, TERT, TELO2 | MAPT 1276/4885MAPK1 2136/4885TSHR 3827/4885 |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | DCX, TERT, TELO2 | MAPT 1276/4885MAPK1 2136/4885TSHR 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.